Epicore BioNetworks IncTSXV: EBN

Epicore BioNetworks Inc. Record Results in Fiscal Year 2007

· Issued by Epicore BioNetworks Inc via CNW

for the period ended 30 June 2007

CALGARY, Oct. 26 /CNW/ - With net income increasing by over 300%, Epicore recorded a positive net income for the fourth year in a row. Despite challenging market conditions in terms of low shrimp prices and in some markets the prevalence of virulent diseases, Epicore's business grew substantially in fiscal 2007 with sales growth in almost every market sector. Revenues increased by over $1 million (56%) with increased sales in the Americas and Asia. Epicore sales exceeded the $3 million mark for the first time. Operational expenses increased by 25% but relative to sales improved from 62% of sales to 50% of sales.

Aquaculture remains the Company's most important market sector, with 97% of total sales. Epicore biotechnology and specialty feed technology offer answers to problems of pollution, disease and poor nutrition in aquaculture operations around the world.

Market conditions appear to have bottomed-out and are recovering slowly after a weak year in 2007. However, Epicore has successfully adapted its product offering to meet changing market situations. The new application method for our EPICIN biological aquaculture treatment continues to provide producers with increased yields in low stocking density farms. To facilitate application to feed, two new formulations of EPICIN were introduced. New lower cost liquid hatchery feeds, sold under the name EPILITE that were developed in response to depressed post-larval shrimp prices sold well in price sensitive markets.

Distributors in Indonesia, Mexico, India, Thailand, Brazil and Venezuela made major contributions to fiscal 2007 results, confirming the value of our mixed marketing approach. Most distributors posted strong year-on-year sales growth. The movement from Penaeus monodon to Penaeus vannamei culture in Asia opened doors at major producers for Epicore's Latin American experience with products for P. vannamei. The shift in species made Indonesia our second largest market in 2007. Latin America remained our largest revenue generator as sales grew 26% in fiscal 2007.

Epicore gross profit increased by $0.7 million, whereas operating expenses increased only by $0.3 million in fiscal 2007. Revenue growth resulted in higher income taxes, which were partially decreased by our accumulated net operating losses. The Company generated a net income of $0.5 million versus $0.1 million in prior year. Basic net income per share was $0.019 versus prior year of $0.005.

                                             (US$)    2007        2006
                                                      ----        ----
Sales                                              3,131,000   2,011,000
Gross Profit                                       2,113,000   1,377,000
Expenses                                           1,557,000   1,249,000
Other Income (Expense)                               (27,000)      6,000
Income Taxes                                          72,000      25,000
Net Income (Loss)                                    457,000     108,000

Cash at the end of June was $0.2 million, a decrease of $0.2 million from prior year mainly due to investment in the Company's New Jersey site. With these funds, expected sales revenue growth and continued relatively low operating costs, management expects there will be sufficient cash to meet the fiscal year's financial requirements, to fund expansion of aquaculture and environmental remediation marketing efforts and to investigate new strategies for enhancing shareholder value.

The financial statements of the Company have been prepared in accordance with Canadian GAAP. Epicore BioNetworks Inc. is a public corporation with a registered office in Calgary, Alberta, Canada and with shares listed on the TSX Venture Exchange (symbol EBN). (The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.)

This press release contains forward-looking statements that involve significant risks and uncertainties. The actual results, performance or achievements of the Company might differ materially from the results, performance or achievements of the Company expressed or implied by such forward-looking statements. Such forward-looking statements include, without limitation, those regarding the development plans of the Company and the expected timing and results of such development. We can provide no assurance that such development will proceed as currently anticipated or that the expected timing or results of such development will be realized. We are subject to various risks, including the uncertainties of product development, markets for our products and regulatory review, our need for additional capital to fund our operations, our reliance on collaborative partners, our history of losses, and other risks inherent in the biotechnology industry.

Epicore BioNetworks Inc on 6ix

Earlier from Epicore BioNetworks

Later from Epicore BioNetworks

All Epicore BioNetworks news releases